Note: Descriptions are shown in the official language in which they were submitted.
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
BIARYL COMPOUNDS HAVING ANTI-INFECTIVE ACTIVITY
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims the benefit of provisional application Serial
No. 60/400,671,
filed August 2, 2002, the entire contents of which are incorporated herein by
reference.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER
FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] NOT APPLICABLE
REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER
PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK.
[0003) NOT APPLICABLE
BACKGROUND OF THE INVENTTON
1. FIELD OF THE INVENTION
[0004] This invention relates to aromatic compounds having antibacterial
activity and
methods for their synthesis and use.
2. DESCRIPTION OF RELATED ART
[0005] The discovery of penicillin and other antimicrobials in the early and
mid 20th
century generated a period of optimism about the medical profession's ability
to treat
microbial infections. However, the evolution of drug-resistant microbe strains
- with new
ones being constantly discovered - has led an appreciation of the continuing
need to develop
new antirnicrobials, preferably ones that are structurally different from
extant ones or employ
a different mechanism of action.
[0006] Exemplary recent disclosures of new antibacterial compounds include Ge
et al., WO
01/74898 (2001); Baird et al., US Application No. 10/132,887, filed Apr. 24,
2002; Biirli et
al., US Application No. IO/165,856, filed Jun. 6, 2002; McMinn et al., US
Application No.
10/165,433, f led Jun. 6, 2002; Biirli et al., US Application No. 10/165,857,
filed Jun. 6,
2002; Biirli et al., US Application No. 10!165,764, filed Jun. 6, 2002.
Matsunaga et al., US
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
5,821,258 (1998) and US 5,852,011 (1998); and Ohemeng et al., US 5,942,532
(1999) also
disclose compounds reportedly having antimicrobial activity.
[0007] Disclosures of compounds that, even though not featured as
antimicrobials, have
chemical structures that may be relevant to the present invention include
Matsunaga et al., US
5,808,087 (1998); JP 11-I7I886 (1999); and JP 11-189594 (1999); Dykstra et
al., US
5,817,686 (1998); Neidle et al., WO 00/63180 (2000); Raspanti, US 5,362,481
(1994);
Dantzig et al., WO 97/17069 (1997); Judd, WO 94/I 1369 (1994); and the IDdb3
database's
Drug Report for the drug Phortress (U. Nottingham).
BRIEF SUMMARY OF THE INVENTION
[0008] The present invention provides a compound (I) according to the formula
Z=Z
~'Z~~~\ /~NR3
Z'z Y Z-Z ~Ar
[0009] O N(R2)2 (1)
and the pharmaceutically acceptable salts thereof,
wherein
each Z is independently N or C(Rl), with the proviso that no more than 2 Z's
in any one
aromatic ring are N;
YisO,N,orS;
Q is N or C(Rl), with the proviso that Q is C(Rl) when Y is N;
Ar is an aromatic or heteroaromatic 5- or 6-member ring;
each Rl is independently H, halogen, OH, or a C1 to C12 alkyl or heteroalkyl
moiety;
each R2 is independently H or a Cl to C1$ alkyl or heteroalkyl moiety or the
two R2's taken
together with the nitrogen atom to which they are attached form a substituted
or
unsubstituted heteroalkyl 5 to 7 member ring;
and
R3 is H or a C1 to C6 alkyl moiety;
with the proviso that at least one group Rl, R2, or R3 contains an alkyl amine
group or a
quaternary nitrogen group.
[0010] Preferably, the alkylamino group or quaternary nitrogen group is
situated in a group
a
R.
2
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
BRIEF DESCRIPTION OF THE DRAWINGS
[OOI1] Figs. 1 to 14 show synthetic schemes related to the preparation of
compounds of this
invention.
DETAILED DESCRIPTION OF THE INVENTION
Abbreviations and Definitions
[0012] The term "alkyl," by itself or as part of another substituent, means,
unless otherwise
stated, a straight or branched chain, or cyclic hydrocarbon radical, or
combination thereof,
which may be fully saturated, mono- or polyunsaturated and can include di- and
multivalent
radicals, having the number of carbon atoms designated (i.e. C1-Clo means one
to ten
carbons). Examples of saturated hydrocarbon radicals include groups such as
methyl, ethyl,
n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclohexyl,
(cyclohexyl)methyl,
cyclopropylmethyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-
heptyl, n-
octyl, and the like. An unsaturated alkyl group is one having one or more
double bonds or
triple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl,
crotyl, 2-
isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, I-
and 3-propynyl,
3-butynyl, and the higher homologs and isomers.
[0013] The term "alkylene" by itself or as part of another substituent means a
divalent
radical derived from an alkane, as exemplified by -CHaCHzCH2CH2-. Typically,
an alkyl (or
alkylene) group will have from 1 to 24 carbon atoms, with those groups having
10 or fewer
carbon atoms being preferred in the present invention. A "lower alkyl" or
"lower alkylene" is
a shorter chain alkyl or alkylene group, generally having six or fewer carbon
atoms.
[0014] The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are
used in their
conventional sense, and refer to those alkyl groups attached to the remainder
of the molecule
via an oxygen atom, an amino group, or a sulfur atom, respectively.
[0015) The term "heteroalkyl," by itself or in combination with another term,
means, unless
otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon
radical, or
combinations thereof, consisting of the stated number of carbon atoms and from
one to three
heteroatoms selected from the group consisting of O, N, Si and S, and wherein
the nitrogen
and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may
optionally be
quatenuzed. The heteroatom(s) O, N and S may be placed at any interior
position of the
heteroalkyl group. The heteroatom Si may be placed at any position of the
heteroalkyl group,
including the position at which the alkyl group is attached to the remainder
of the molecule.
3
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Examples include -CH2-CH2-O-CH3, -CH2-CHZ-NH-CH3, -CH2-CHZ-N(CH~)-CH3, -CHZ-S-
CH2-CH3, -CHZ-CH2,-S(O)-CH3, -CH2-CHZ-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -
CH2_
CH=N-OCH3, and -CH=CH-N(CH3)-CH3. Up to two heteroatoms may be consecutive,
such
as, for example, -CH2-NH-OCH3 and -CHZ-O-Si(CH3)3. Similarly, the term
"heteroalkylene"
by itself or as part of another substituent means a divalent radical derived
from heteroalkyl, as
exemplified by -CHZ-CH2-S-CHZCHa- and -CH2-S-CHI-CH2-NH-CH2-. For
heteroalkylene
groups, heteroatoms can also occupy either or both of the chain termini (e.g.,
alkyleneoxy,
alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further,
for alkylene and
heteroalkylene linking groups, no orientation of the linking group is implied.
[0016] The terms "cycloalkyl" and "heterocycloalkyl", by themselves or in
combination
with other terms, represent, unless otherwise stated, cyclic versions of
"alkyl" and
"heteroalkyl", respectively. Additionally, for heterocycloalkyl, a heteroatom
can occupy the
position at which the heterocycle is attached to the remainder of the
molecule. Examples of
cycloalkyl include cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl,
cycloheptyl, and
1S the like. Examples of heterocycloalkyl include 1 -(1,2,5,6-
tetrahydropyridyl), 1-piperidinyl,
2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-
yl, tetrahydro-
furan-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yI, 1 -piperazinyl, 2-
piperazinyl, and the
like.
[0017] The terms "halo" or "halogen," by themselves or as part of another
substituent,
mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
Additionally,
terms such as "haloalkyl," are meant to include monolialoalkyl and
polyhaloalkyl. For
example, the term "halo(C1-C4)alkyl" is meant to include trifluoromethyl,
2,2,2-
trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0018] The term "aryl" means, unless otherwise stated, a polyunsaturated,
typically
ZS aromatic, hydrocarbon substituent which can be a single ring or multiple
rings (up to three
rings) which are fused together or linked covalently. The term "heteroaryl"
refers to aryl
groups (or rings) that contain from zero to four heteroatoms selected from N,
O, and S,
wherein the nitrogen and sulfur atoms are optionally oxidized, and the
nitrogen atoms) axe
optionally quaternized. A heteroaryl group can be attached to the remainder of
the molecule
through a heteroatom. Non-limiting examples of aryl and heteroaryl groups
include phenyl,
1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-
pyrazolyl, 2-
imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-
oxazolyl, S-oxazolyl,
4
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-
thiazolyl, 2-furyl, 3-furyl,
2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-
pyrimidyl, 5-
benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-
isoquinolyl, 2-
quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for
each of the above
noted aryl and heteroaryl ring systems are selected from the group of
acceptable substituents
described below.
[0019] For brevity, the term "aryl" when used in combination with other terms
(e.g.,
aryloxy, arylthioxy, arylalkyl) includes both aryl and heteroaryl rings as
defined above.
Thus, the term "arylalkyl" is meant to include those radicals in which an aryl
group is
attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the
like) including
those alkyl groups in which a carbon atom (e.g., a methylene group) has been
replaced by, for
example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl, 3-(1-
naphthyloxy)propyl, and the like).
[0020] Each of the above terms (e.g., "alkyl," "heteroalkyl," "aryl" and
"heteroaryl") are
meant to include both substituted and unsubstituted forms of the indicated
radical. Preferred
substituents for each type of radical are provided below.
[0021] Substituents for the alkyl, heteroalkyl, aryl, and heteroalkyl radicals
(including those
groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl,
alkynyl,
cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be a
variety of
groups selected from: -OR', =O, =NR', =N-OR', -NR'R", -SR', -halogen, -
SiR'R"R"',
-OC(O)R', -C(O)R', -C02R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'-
C(O)NR"R"°,
-~»C(O)2R~~ -~-C(~2~ ~~ _~~C(~2)°NH~ -NH-C(NHZ)=NR', -S(O)R', -S(O)zR',
-S(O)ZNR'R", -CN and -N02 in a number ranging from zero to (2m'+1), where m'
is the total
number of carbon atoms in such radical. R', R" and R"' each independently
refer to
, hydrogen, unsubstituted (C1-C$)alkyl and heteroalkyl, unsubstituted aryl,
aryl substituted with
1-3 halogens, unsubstituted alkyl, alkoxy or thioalkoxy groups, or aryl-(Ci-
C4)alkyl groups.
When R' and R" are attached to the same nitrogen atom, they can be combined
with the
nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is
meant to
include I-pyrrolidinyl and 4-morpholinyl. From the above discussion of
substituents, one of
skill in the art will understand that the term "alkyl" is meant to include
groups such as halo-
allcyl (e.g., -CF3 and -CHaCF3) and acyl (e.g., -C(O)CH3, -C(O)CF3, -
C(O)CH20CH3, and the
like). Preferably, the substituted alkyl and heteroalkyl groups have from 1 to
4 substituents,
S
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
more preferably 1, 2 or 3 substituents. Exceptions are those perhalo alkyl
groups (e.g., penta-
fluoroethyl and the like) which are also preferred and contemplated by the
present invention.
[0022] Similarly, substituents for the aryl and heteroaryl groups are varied
and are selected
from: -halogen, -OR', -OC(O)R', -NR'R", -SR', -R', -CN, -N02, -C02R', -
CONR'R",
_~(~)R~, -o~(o)~~R», -~»C(o)R~~ -~»C(o)aR=> >-~'-C(o)NR"R»a, -S(o)2R>>
-NH-C(NH2)--NH, -NR'C(NH2) NH, -NH-C(NH2)-NR', -S(O)R', -
S(O)zNR'R°°, _N3, -
CH(Ph)2, perfluoro(C1-C4)alkoxy, and perfluoro(Cl-C4)alkyl, in a number
ranging from zero
to the total number of open valences on the aromatic ring system; and where
R', R" and R"'
are independently selected from hydrogen, (C1-C8)alkyl and heteroalkyl,
unsubstituted aryl
and heteroaryl, (unsubstituted aryl)-(C1-C4)alkyl, and (unsubstituted aryl)oxy-
(CI-C4)alkyl.
[0023] Two of the substituents on adjacent atoms of the aryl or heteroaryl
ring may
optionally be replaced with a substituent of the formula -T-C(O)-(CHa)q U-,
wherein T and U
are independently -NH-, -O-, -CHZ- or a single bond, and q is an integer of
from 0 to 2.
Alternatively, two of the substituents on adjacent atoms of the aryl or
heteroaryl ring may
optionally be replaced with a substituent of the formula -A-(CHZ)r B-, wherein
A and B are
independently -CH2-, -O-, -NH-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'- or a single
bond, and r is an
integer of from 1 to 3. One of the single bonds of the new ring so formed may
optionally be
replaced with a double bond. Alternatively, two of the substituents on
adjacent atoms of the
aryl or heteroaryl ring may optionally be replaced with a substituent of the
formula -(CH2)s-
X-(CH2)t-, where s and t are independently integers of from 0 to 3, and X is -
O-, -NR'-, -S-, -
S(O)-, -S(O)a-, or -S(O)2NR'-. The substituent R' in -NR'- and -S(O)2NR'- is
selected from
hydrogen or unsubstituted (Ci-C6)alkyl.
[0024] As used herein, the term "heteroatom" is meant to include oxygen (O),
nitrogen (I~,
sulfur (S) and silicon (Si).
[0025] The term "pharmaceutically acceptable salts" is meant to include salts
of the active
compounds which are prepared with relatively nontoxic acids or bases,
depending on the
particular substituents found on the compounds described herein. When
compounds of the
present invention contain relatively acidic functionalities, base addition
salts can be obtained
by contacting the neutral form of such compounds with a sufficient amount of
the desired
base, either neat or in a suitable inert solvent. Examples of pharmaceutically
acceptable base
addition salts include sodium, potassium, calcium, ammonium, organic amino, or
magnesium
salt, or a similar salt. When compounds of the present invention contain
relatively basic
6
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
functionalities, acid addition salts can be obtained by contacting the neutral
form of such
compounds with a sufficient amount of the desired acid, either neat or in a
suitable inert
solvent. Examples of pharmaceutically acceptable acid addition salts include
those derived
from inorganic acids Like hydrochloric, hydrobromic, nitric, carbonic,
monohydrogen-
carbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric,
monohy-
drogensulfuric, hydriodic, or phosphorous acids and the like, as well as the
salts derived from
relatively nontoxic organic acids like acetic, ascorbic, propionic,
isobutyric, malefic, malonic,
lactic, malic, glutamic, benzoic, succinic, suberic, fumaxic, mandelic,
phthalic, benzenesul-
fonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, lactobionic, and
the like. Also
included are salts of amino acids such as arginate and the like, and salts of
organic acids like
glucuronic or galactunoric acids and the like (see, for example, Berge, S.M.,
et al,
"Pharmaceutical Salts", .Iou~hal ofPha~maceutical Science, 1977, 66, 1-19).
Certain specific
compounds of the present invention contain both basic and acidic
functionalities that allow
the compounds to be converted into either base or acid addition salts.
[0026] The neutral forms of the compounds may be regenerated by contacting the
salt with
a base or acid and isolating the parent compound in the conventional manner.
The parent
form of the compound differs from the various salt forms in certain physical
properties, such
as solubility in polar solvents, but otherwise the salts are equivalent to the
parent form of the
compound for the purposes of the present invention.
[0027] In addition to salt forms, the present invention provides compounds
which are in a
prodrug form. Prodrugs of the compounds described herein are those compounds
that readily
undergo chemical changes under physiological conditions to provide the
compounds of the
present invention. Additionally, prodrugs can be converted to the compounds of
the present
invention by chemical or biochemical methods in an ex vivo environment. For
example,
prodrugs can be slowly converted to the compounds of the present invention
when placed in a
transdermal patch reservoir with a suitable enzyme or chemical reagent.
[0028] Certain compounds of the present invention can exist in unsolvated
forms as well as
solvated forms, including hydrated forms. In general, the solvated forms are
equivalent to
unsolvated forms and are intended to be encompassed within the scope of the
present
invention. Certain compounds of the present invention may exist in multiple
crystalline or
amorphous forms. In general, all physical forms are equivalent for the uses
contemplated by
the present invention and are intended to be within the scope of the present
invention.
7
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0029] Certain compounds of the present invention possess asymmetric carbon
atoms
(chiral centers) or double bonds; the racemates, diastereomers, geometric
isomers and
individual isomers are all intended to be encompassed within the scope of the
present
invention.
[0030] The compounds of the present invention may also contain unnatural
proportions of
atomic isotopes at one or more of the atoms that constitute such compounds.
For example,
the compounds may be radiolabeled with radioactive isotopes, such as for
example tritium
(3H), iodine-125 (12s~ or carbon-14 (14C). All isotopic variations of the
compounds of the
present invention, whether radioactive or not, are intended to be encompassed
within the
scope of the present invention.
Compounds
[0031] Preferred embodiments of compound (I) of this invention are now
discussed.
-Z~ Q Z=Z
~~\ /~NR3
Z~Z Y Z-Z ~-Ar
[0032] O N(R2)2 (1)
[0033] The 6,5-fused ring system in compound (I)
.Z
Z
Z'Z~Y
preferably is selected from the group consisting of
R~ R~ R~ R~ R~
R~ ~ W \ ~ R~ ~ ~ \ ~ R~
R~ / O R~ .i S~ R~ .i S
R~ R~ R~
R~ R~ R~
R~ N R~
and ~ ~
R1 ~ ~ R1 / ~ r
R~ R~ H
(where Rt is as previously defined, with H and CH3 being preferred R1 groups);
with the
following 6,5-fused ring systems being particularly preferred:
8
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
~ \ I ~ \ I ~ N~
O ~ S H3C ~ S
H3C N
I ~ \ and I ~ \
N ~ O
H
[0034) The 6-member ring
Z-Z
y
Z=Z
adjacent to the 6,5-fused ring system preferably is selected from the group
consisting of
R1 R1 R1 R1 R1 R1
and /
\ / v
R1 R1 R1 R1 R1
(where R1 is as previously defined, with H and CH3 being preferred R1 groups);
with the
following 6-member rings being particularly preferred:
H3C
/ \ ~ / ~d
[0035] The divalent residue
-A\
preferably is selected from the group consisting of
R7 R~ R~ R~
X ~X2
/ \~-R7 and / \ R7
X1~ -.N 7
R
wherein one of X1, X2, and X3 is a ring vertex selected from the group
consisting of -O-, -S-,
and -NRg-, and the other two of Xl, X2, and X3 are ring vertices selected from
the group
consisting of =N- and =CRS-; each R' is independently H, F, Cl, Br, I, CN, OH,
NOZ, NHZ, a
substituted or unsubstituted (C1-CIZ)allcyl group, a substituted or
unsubstituted (Cl-
9
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
C12)alkoxy group, or a substituted or unsubstituted (C1-C12)heteroalkyl group;
and R8 is H, a
substituted or unsubstituted (Cl-C12)alkyl group, or a substituted or
unsubstituted (C1-
C12)heteroalkyl group.
[0036] The residue
X~Xz
X ~.s'
is a 5-rnembered ring heteroaromatic moiety, the selection of Xl, X2, and X3
determining the
type of heteroaromatic ring. Exemplary heteroaromatic rings include imidazole,
pyrrole,
pyrazole, furan, isothiazole, oxazole, isoxazole, thiazole, furazan, 1,2,3-
thiadiazole, 1,2,4-
thiadiazole, 1,25-thiadiazole, 1,3,4-thiadiazole, 1,2,3-triazole, 1,2,4-
triazole, 1,3,4-
oxadiazole, 1,2,4-oxadiazole, and thiophene. The circle in the five-membered
rings of
formula is meant to indicate the presence of two double bonds, which, in some
embodiments,
can move within the ring.
[0037] Specific examples of moieties
-A\
include
N,S and / ~ CI
-N
CI
[0038] Compounds (n have an alkyl amine group or a quaternary nitrogen group.
Exemplary amine groups include
-NHz ~NH(CH3) ~--N(CH3)z ~-N(CH3)z
-N~ ~-N~Q (Q = CH2, O, S, NH)
and the like. Exemplary quaternary nitrogen groups include
O +~W
i i ~+ ~ ~ ~ / ~ N(CH3)s ~~ J (W = CH2, O~ S)
CH3 H3C
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0039] In a preferred embodiment, each R2 is attached to the nitrogen atom via
an spa
carbon, as illustrated by the following illustrative groups N(RZ)z.
R25 R25 ~S R25
N~(CHz)r~N(R25)z ~ N~(C~"~2)r~N~ ~ N~(CH2)rrN (CHz)rCH3
Rz5 R25 ~O R25 ~N_R25
N~ ~N~ ~ N~ ~N J -N~ N
(CHz)r (CH2)r ~ (CH2)r~
Rz5 R25 / Rz5 Rz5 Rz5
-N ~ ~ N ~ ( ~-N ~ ~ N ~-N ~ N
(CHz)r (CH2)r (CHz)r
Rz5 Rz5 Me Me Rz5 (CH2)r-N(R25)2
~N~(CHz)r~N~ ~\N~N(Rz5)z ~N~CCH2)r~N~(CH2)r-N(Rz5)z
Rz5 Rz5
and ~N~(CH2)r~N
[0040] The two R2's can join together with the nitrogen atom to which they axe
attached to
form a 5, 6, or 7 member ring, as in
~N_R25 ~N~N(R25)z
~N~N_Rzs ~-N J ~d ~-N
[0041] In the foregoing formulae, r is an integer ranging from 2 to ~,
inclusive (preferably 2
to 6), and each Rzs is independently H, CH3, CH2CH3, CH2CH2CH3, or CH(CH3)z.
[0042] Specific preferred N(Rz)z groups include:
.s'~~H~N~NH2 s~~H~-~N(CH3)2 ~\N~NH2
CH3 H
,s~~N~O~C.~NH2 s~~N~N(CH2CH3)2 ~\N~NH2
H H H
.yN~N(CH2CH3)s -yN~NH2 .yN~N~
H H H
11
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
S
W ~ ~ W ~N~
N N N N''~
H H H H
.syNr~N~ s~N~ s~N~
H ~O ~N~NH2 ~ ~NH
~NH ~O ~N'CH3
syN~N J syN~N J and .ss''wN~N~
H H H
[0043] R3 preferably is H, but it may be an alkyl group such as methyl, ethyl,
propyl,
isopropyl, butyl, t-butyl, and the like.
[0044] Preferred subgenera of compounds (I) are
I NH N,
/ O ~ / ~ S I / O ~ / NH
O
O~~ N(R2)2
CI (R2)2N
I ~ O ~ / NH CI I / O ~ / NH
O~ H C O \ N
3
(R2)2N (R2)2N
I / O ~ / NH N~S I , O N / NH N~S
' H3C O~~N(R2)2 O~~N(R2)
CI CI 2
/ ~ ~ / NH N~S I r ~\ ~ ~ / NH
S O N ~ / CI
O
O ' N(R2)2 (R2)2NY
CI
_ H3C N _
S ~ / NH I ~ O ~ / NH N,S
O \ N O~r~N(R2)2
(R2)2N CI
12
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
I ~ N \ / NH N~S I ~ ~ \ \ / NH
_ N
H O~~N(R2)2 H O \ N
CI (R2)2N
/ ~ \ / NH N~S I , ~ \ ~ NH
S N ~~ S N
O ' N(R2)2 O~N
CI (R2)2N
N
I o ~ \ / NH N,S and
H3C g i
O ~N(R2)
CI 2
w
~ \ / NH
O N /
O
(R2)2N
and the pharmaceutically acceptable salts thereof,
wherein each R2 is independently H or a Ci to C18 alkyl or heteroalkyl moiety
or the two Rz's
IO taken together with the nitrogen atom to which they are attached form a
substituted or
unsubstituted heteroalkyl 5 to 7 member ring; at least one group R~ containing
an alkyl amine
group.
[0045] Examples of specific compounds (T) are shown in Table A.
[0046]
Table A - Exemplary Compounds of Formula (I)
.Z~ Q
Ref.
Z\Z~ ~A~ ~N(R2)2
Y Z-Z
/ \ N\S ~NH
A-1 ~ ~ O ~~ ~-~ .yN ~ N
CI H
A-2 Same Same Same "~~N~NH2
H
A-3 Same Same Same ~~N~NH2
H
A-4 Same Same Same -s'~~N'~NH2
H
13
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
A-5 Same Same Same '~~N'~N(CH2CH
)2
3
H
A-6 Same Same Same '~~N~p~p~'NHZ
H
A-7 Same Same Same '~~N'~N(CH3)2
H
A '~
S ~~
~
- Same Same Same N
NH2
H
CH3
A-9 Same Same / N' '~~N~NH
2
H
~NH
A-10 Same Same Same ,~~N~N J
H
A-11 Same Same Same '~~N~N(CH3)2
H
14
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table A (continued)
.z
Ref.
v / \ ~A~ ~N(R2)2
Z'Z Y Z=Z
r ~
A-1~ ~ ~ ~ r v _ ~ .r~ ~
p ~~ N N
H H
A-13 Same Same Same ~'~ ~N~
N
H
~S
A-14 Same Same Same .~'~~N~N~
H
A-15 Same Same Same -s'vN~N~
H
A-16 Same Same Same ~~N~N'~
H ~O
''-~N~
A-17 Same Same Same ~N
~NH2
A-18 Same Same Same ~~N~NH2
H
A-19 Same Same Same -~~N~NH2
H
"r~N~
A-20 Same Same Same
~NH
A-21 Same Same Same -s'~~N~N(CH2CH3)3
H
A-22 Same Same Same '~~N''~p~p~NH2
H
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table A (continued)
. Z ~Q~ ~Z-
Ref.
Z ' ~ ~A~ ~N(R2)2
Z Y Z=Z
A-23 I / ~ / \ CI ~~N'~N(CH2CH3)2
O H
A-24 Same Same Same '~~N~p~p~NH2
H
A-25 Same Same Same -s'vN~N~
H
~NH
A-26 Same Same Same ,.~~N ~N J
H
/\ /\~
A-27 Same -N ~'~ ~N~
N
HsC H
~NH
A-28 Same Same Same ,~'~N.~N J
H
A-29 Same Same Same '~~N~NH2
H
A-30 Same Same Same '~~N~N(CH3)2
H
A-31 Same Same Same ~~H~N'~NH2
CH3
N~S
A-32 Same Same ~-- ~'~ ~N~
N
CI H
A-33 Same Same Same -~~N~NHZ
H
16
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table A (continued)
-z Q z-z
Ref. Z ~Y~----
~N(R2)2
z'z Z=Z
N~S
A-34 ~ ~ ~ ~-~ '~~N~NH2
HsC CI H
~NH
A-35 Same / ~ Same ~''~N~N J
N
H
A-36 Same Same Same "~~N~N(CH3)2
H
A-37 Same Same Same ~~N-'~/~NH2
H
A-38 Same Same Same '~~N~NH2
H
A-39 Same Same -N '~~N~N~NH~
H CHs
A-40 Same Same Same '~~N~NH2
H
A-41 Same Same CI ~~N~N~NH2
H 'CHs
~NH
A-42 Same Same Same ~'''~N.~N J
H
A-43 Same Same Same -~~N~-N
H
A-44 Same Same Same "~~N~N(CHs)2
H
17
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table A (continued)
,Z
Ref. Z. ~~~ ~Z ~ ~A~ ~N(1~2)2
Z Y Z=Z
A-45 I \ ~ / ~ / \ CI s~~N~NH2
/O
H
N,S
A-46 ~ \ ~ / 1 ~ ~ '.~'~~ N ~ N
H
CI
A-47 Same Same Same "~~N'~N(CH3)2
H
A-48 Same Same / \ ~NH
~N .yN.~N~
H
A-49 Same Same Same -~~N~N~
H
A-50 Same Same Same ~~N'~N(CH3)2
H
N N,S
A-51 ~ , S~ Same -- ~N~N'~NH2
HC
s CI CHs
A-52 Same Same Same '~~N~NHZ
H
A-53 Same Same Same ~~N~NH2
H
A-54 Same Same Same "'~~N'~N(CH3)2
H
H3C N
A-55 ~ ~ ~ Same Same Same
O
18
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table A (continued)
.Z
Ref. z ~~~---~ ~---CZ- >-- ~--
Z 'Z ~A~ ~'N(R2)2
Z=Z
N,S
A-56 ~ ~ ~ / \ ~~ .yN~NH2
N
H C~ H
A-57 Same Same Same '~~N'~N(CH3)~
H
A-58 Same Same Same -~~N~N~
~'H
~NH
A-59 Same Same Same ,.~'~N ~N J
H
~O
A-60 Same Same Same ,.~~N~.N~
H
~N.CH3
A-61 Same Same Same ,~'~N~N J
H
A-62 Same Same / N~ -~~N'~NH2
H
A-63 Same Same Same '~~N'~N(CH3)2
H
~NH
A-64 Same Same Same ,~'~N~N J
H
N,CH3
A-65 Same Same Same ,~'~N~N J
H
19
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table
A
(continued)
,Z
Ref. z ~~~--~ ~---CZ- ~A~ ~N(R2)z
>---
Z ' ~ Z=Z
Z Y
~O
A-66 ~ ~ ~ , - ,~~ ~ N
N ~~
N
H H
N,S
A-67 ~ ~ ~ ~ ~ ~~ -~~N~N~CH3)2
~-~/~
S N H
CI
A-6S Same Same Same '~~N-'~/~NH2
H
A-69 Same Same Same ,.~ ~N~
N
H
~NH
A-70 Same Same Same ,~~N.~N J
. H
~
~~
'~'~
A-71 Same Same Same N
NH2
H
CH3
A-72 Same Same -N ,.~''~ ~N~
N
H
~NH
'
A-73 Same Same Same ,~
~N,~N J
H
A-74 Same Same Same '-'~~N~N(CH3)2
H
A-75 Same Same Same '~~N'~NH2
H
'~
~~
~
A-76 Same Same Same N
NHZ
H
CH3
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0047] In the entries in Table A, where a divalent residue
Z-Z
or ~-Ar
Z=Z
is asymmetric, it is to be inserted into formula (I) in the orientation
depicted to arrive at the
specific compound at issue. (This statement is not to be construed as meaning
that such an
asymmetric residue only can be used in compounds of this invention in the
depicted
orientation; in the context of a different compound, it can be used in the
reversed orientation.)
By way of illustration, the fully written out structure of compound A-32 is
w
NH N,S
O ~,
H3C O~~N'~N
CI H
while the fully written out structure of compound A-39 is
.-
~ NH
N ~ ~ NH2
O~-\--N
HN~-N
CH3
and the fully written out structure of compound A-45 is
I / ~ ~ ~ NH
O N ~ ~ CI
O
HN~NHZ
and so forth.
[0048] Compounds of this invention have been found to have anti-bacterial
and/or
antifungal properties and therefore may be used fox combating (i.e.,
preventing and/or
treating) infections in eukaryotic organisms. For human anti-infective
applications, an
effective amount of a compound of this invention is used, optionally in
combination with a
pharmaceutically acceptable carrier. The composition may be dry, or it may be
a solution.
Treatment may be reactive, for combating an existing infection, or
prophylactic, for
preventing infection in an organism susceptible to infection. Preferably,
compounds of this
invention are used to treat infections by drug-resistant strains of bacteria,
for example MRSA
21
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
(methicillin resistant S. aureus), MRSE (methicillin resistant S.
epidermidis), PRSP
(penicillin resistant S. pueumohiae) or VRE (vancomycin resistant
Enterococci). By "drug-
resistant" it is meant that the bacteria are resistant to treatment with
conventional antibiotics.
[0049] Host organisms that can be treated include eukaryotic organisms, in
particular plants
and anmals. The plant may be an agriculturally important crop, such as wheat,
rice, corn,
soybean, sorghum, and alfalfa. Anmals of interest include mammals such as
bovines,
canines, equines, felines, ovines, porcines, and primates (including humans).
Thusly, in
another aspect of this invention, there is provided a method for treating a
bacterial infection
- particularly an infection by Gram-positive bacteria - comprising
administering to a
patient in need of such treatment an effective amount of compound (I).
Compounds of this
invention can be used in the preparation of a medicament for treating a
bacterial infection in a
mammal. The compounds may be administered orally, topically, parenterally
(e.g.,
intravenously, subcutaneously, intraperitoneally, transdermally) or by
inhalation.
Synthesis - General Remarks
[0050] Typically, the structures of compounds were confirmed by 1H-NMR and/or
mass
spectrometry. Where a parenthetical remark such as "1H-NMR" or "mass spectrum"
or "ESI-
MS" follows a reference to a compound without any elaboration, it means that
such spectrum
was taken, was consistent with the assigned structure, and did not indicate
the presence of
significant impurities.
[0051] Abbreviations in common usage are employed for various technical terms,
solvents,
catalysts and reagents, including: HBTU for 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyl-
uronium hexafluorophosphate; DIEA for diisopropylethylamine; DMF for N,N-
dimethyl-
formamide; TFA for trifluoroacetic acid; NMP for N-methylpyrrolidone; Boc for
t-butyl-
oxycarbonyl; RT for room temperature; and TLC for thin layer chromatography.
[OOS2] The skilled artisan will understand: (a) that an intermediate described
in the context
of the synthesis of a particular compound of this invention can also be used
to make other
compounds of this invention, mutatis mutandis; (b) that in certain
experimental sections only
the preparation of an intermediate compound is described, because its
incorporation into a
final compound of this invention straightforwardly follows synthetic
methodology described
herein; and (c) that, for some reactions that recur herein, detailed reaction
and work-up
conditions sometimes are not provided in each instance in the interest of
brevity and that the
22
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
conditions described elsewhere in this application are adaptable to the
instance at hand
without undue experimentation.
Synthesis - General Procedures
[0053] The following recurring general procedures are cited as "Procedure A,"
"Procedure
B," etc. in the subsequent experimental sections.
[0054] Procedure A: Suzuki-type coupling of a boronic acid and an aryl halide.
A degassed
suspension of the boronic acid (l.l equiv.), PdCl2(PPh3)Z (0.05 equiv.), and
Na2CO3 (5
equiv.) in DMF/H20 (2:1) was treated at RT under NZ with a degassed (N2)
solution of the
aryl halide (1.0 equiv.) in DMF (1/4 of total volume). The mixture was heated
to 80°C for 3hr
(the reaction was followed by TLC and worked up after complete consumption of
the starting
material), cooled to RT, diluted with AcOEt, and washed with HZO (2x). The
organic layer
was dried (MgS04) and evaporated. The crude product was purified by flash
chromatography
to give the product as a solid.
[0055] Procedure B: Dep~otection of a Boc-Protected Anaine. A mixture of the
Boc-
protected amine (1 equiv.) in TFA was stirred at RT for 1 hr, treated with
MeOH (1/2 of
reaction volume), and left for 15 min. Evaporation of the solvent gave the
deprotected amine
product, used without further purification.
[0056] Procedure C: Couplin~of an acid chloride to an aryl amine. A mixture of
the acid
chloride (1.2 equiv.) and the amine (1.0 equiv.) in DMF/DIEA (ca. 3:1) was
stirred at 60°C
for 12-18 hr. The mixture was added dropwise to ice-water containing ca. 10%
KZC03 (ca. 40
fold the reaction volume). The resulting precipitate was collected by
filtration and dried.
[0057] Procedure D: Nucleophilic aromatic substitution. A mixture of a
dichloroisothiazole, a 2-chloronicotinamide, or a 4-chloro-2-fluorobenzamide
(1 equiv.) in a
solution of an amine in NMP (2:1) was stirred at 60-75°C for 24 to 72
hr and diluted with
50% aqueous AcOH to a final volume of 15 mL (where noted below, DIEA was added
to the
reaction mixture). The crude product was purified by RP-HPLC (Hamilton PRP-I
column,
CH~CN/0.5% aq AcOH, 0% to 60% in 60 min). The purified product was
characterized by
1H-NMR and ESI-MS).
23
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Synthesis - Compounds
Exam lp a A
[0058] This example describes the synthesis of compounds (~ containing a
benzofuryl-
phenylene moiety.
[0059] Reference is made to Fig. 1, which shows the preparation of
intermediates 11 to 13.
Instead of acid chlorides 6, 8, and 10, the corresponding acids can be used to
prepare
intermediates 11,12, and 13 (using HBTU-mediated coupling).
[0060] Compound 3. A mixture of 4-iodoaniline 2 (9.39 g, 42.8 mmol) and BocaO
(8.78 g,
47.1 mmol) in DMF (25 mL) and DIEA (5 mL) was stirred at RT for 3 hr, diluted
with
AcOEt (300 mL), and washed with H20 (2x, each 150 mL). The organic layer was
dried
(MgS04) and evaporated to give compound 3 (11.89 g, 87%, 1H-NMR).
[0061] Cornpourad 4. Coupling of compounds 1 (679 mg, 4.19 mmol) and 3 (1.21
g, 3.79
mmol) according to procedure A gave compound 4 (0.50 g, 43%, white powder, 1H-
NMR).
[0062] Compound S. A solution of compound 4 (472 mg) in AcOEt (150 mL,
saturated
with anhydrous HCl gas) was stirred at RT for 4 hr and diluted with Et2O (100
mL). The
resulting precipitate was collected by filtration and dried to give compound 5
(315 mg, >95%,
iH-~).
[0063] Compound 11. A mixture of acid 7 (1.06 g, 5.35 mmol) and HBTU (1.93 g,
5.09
mmol) in NMP (4 mL) and DIEA (1 mL) was stirred at RT for 40 min and added to
a
solution of compound 5 (0.935 g, 4.47 mmol) in NMP (2 mL) and DIEA (0.5 mL).
The
mixture was stirred for 1 hr at RT and added dropwise to 10% aqueous KaC03
(200 mL) at
ca. 4°C. The resulting precipitate was collected by filtration and
dried in vacuo to give
compound 11 (1H-NMR; used without further purification).
~0064J Compound 12. A mixture of acid 9 (1.04 g, 6.62 mmol) and HBTU (2.39 g,
6.30
mmol) in NMP (9 rnL) and DIEA (1.5 mL) was stirred at 37°C for 30 min
and added to a
solution of compound 5 (1.16 g, 5.55 mmol) in NMP (2 mL) and DIEA (0.5 mL).
The
mixture was stirred for 17 hr at RT followed by 5 hr at 60°C and added
dropwise to 10%
aqueous KZC03 (400 mL) at ca. 4°C. The resulting precipitate was
collected by filtration and
dried in vacuo to give compound 12 (1.70 g; 1H-NMR spectrum; contained
impurities but
was used without further purif cation).
24
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0065] Compound 13. Coupling of acid chloride 10 (0.222 mL, 1.68 mmol) and
compound
S (0.318 g, 1.29 mmol) according to Procedure C gave compound 13 as a tan
solid (505 mg,
1H-NMR; contained minor impurities but was used without further purification).
[0066] Next, Fig. 2 illustrates the synthesis of compounds A-1 to A-26 from
intermediates
previously synthesized. The regioselectivity of the nucleophilic aromatic
substitution at the
isothiazole unit in intermediate 11 was confirmed by the X-ray structure of a
model
compound, while the structures of compounds A-23 to A-26 were unambiguously
assigned
by 1H-NMR.
[0067] Compounds A-1 to A-8. These compounds were prepared from compound 11
(70
I O mg) in a mixture of the corresponding amine (0.3-1 mL) and NMP (0.1-0.5
mL), 60°C, 24
hours, according to Procedure D.
[0068] Compounds A-9 to A-22. Compounds A-11 and A-13 to A-21 were prepared
from
compound 12 (80 mg) and the corresponding amine (ca. 0.2 mL) in NMP (1 mL) and
DIEA
(0.2 mL), 60°C, 17-24 hr, according to Procedure D. Compounds A-9, A-
10, A-12, and A-22
were prepared analogously.
[0069] Compounds A-23 to A-26. These compounds were prepared from compound 13
(50
mg) in a mixture of the corresponding amine (0.4 mL) and NMP (0.4 mL),
75°C, 24 hr,
according to Procedure D.
Exam lp a B
[0070] This example describes the synthesis of biaryl compounds wherein the
biaryl moiety
comprises a benzofuryl unit and a methylated phenyl unit.
[0071] The synthesis of the intermediates 18 and 19 is shown in Fig. 3.
[0072] Compound I5. Compound 15 was prepared by Boc-protection of aniline 14
by
analogy to the preparation of compound 3.
[0073] Compound 16. Coupling of compounds I (1.55 g, 9.60 mmol) and 15 (2.50
g, 8.73
mmol) according to Procedure A gave intermediate 16 (2.00 g, 71 %, white
solid, 1H-NMR).
[0074] Cornpourt.d 17. Deprotection of intermediate 16 (2.00 g) according to
Procedure B
gave compound 17 (>95%, white solid, 1H-NMR).
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0075] Compound 18. Coupling of compounds 17 (0.70 g, 2.07 mrnol) and 6 (0.494
g, 2.28
mmol) according to Procedure C gave compound 18 (1H-NMR).
[0076] Compound 19. Coupling of compounds,17 (0.70 g, 2.07 mmol) and 8 (0.40
g, 2.28
mmol) according to Procedure C gave compound 19 (1H-NMR).
[0077) Intermediates 18 and 19 were converted to compounds A-27 to A-34, as
shown in
Fig. 4.
[0078] Compounds A-27 to A-31. These compounds were prepared from compound 19
(80
mg) in a mixture of the corresponding amine H2NR2 (0.4 mL) and NMP (1 mL),
70°C, 72 hr,
according to Procedure D.
[0079] Compounds A-32 to A-34. These compounds were prepared from compound 18
(80
mg) in a mixture of the corresponding amine HZNR2 (0.4 mL) and NMP (1 mL),
70°C, 72 hr,
according to Procedure D.
Example C
[0080] This example describes the synthesis of compounds containing a
benzofuryl moiety
and various N-termini. The internal heterocyclic unit is a disubstituted
pyridine. Inter-
mediates 24 to 26 were prepared by Suzuki-type coupling of benzofuryl boronic
acid 1 and
chloropyridine 21 as the key step, as shown in Fig. 5.
[0081] Compound 21. A mixture of pyridine 20 (5.37 g, 41.9 mmol) and Boc2O
(8.56 g,
46.1 mmol) in DMF (25 mL) and DIEA (5 mL) was stirred at RT fox 4 hr, then at
60°C for 16
hr. The solution was diluted with AcOEt (300 mL) and was washed with 10%
aqueous
KZC03 (2x, each 100 mL). The organic layer was dried (MgS04) and evaporated to
give
compound 21 (8.27 g, 87%,1H-NMR).
[0082] Compound 22. Coupling of boronic acid 1 (841 mg, 5.19 mmol) and
compound 21
(1.08 g, 4.72 mmol) according to Procedure A gave compound 22 (1.07 g, 73%,
white
crystals, 1H-NMR).
[0083] Compound 23. A mixture of compound 22 (0.98 g) in AcOEt (50 mL,
saturated
with anhydrous HCl gas) was stirred at 0°C to RT for 9 hr and treated
with Et20 (200 mL).
The resulting solid was collected by filtration and dried to give compound 23
as yellow
crystals (0.759 g, 85%, iH-NMR).
26
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0084] Compound 24. Coupling of acid chloride 6 (1.34 g, 6.17 mmol) and
compound 23
(2.00 g, 6.17 mmol) according to Procedure C gave compound 24 (1H-NMR).
[0085] Compound 25. Coupling of acid chloride 8 (1.09 g, 6.17 mmol) and
compound 23
(2.00 g, 6.17 mmol) according to Procedure C gave compound 25 (1H-NMR; minor
impurities but used for the next step without further purification).
[0086] Compound 26. Coupling of acid chloride IO (0.815 mL, 6.17 mmol) and
compound
23 (2.00 g, 6.17 mmol) according to Procedure C gave compound 26 (1H-NMR;
minor
impurities but used for the next step without further purification).
[0087] The conversion of intermediates 24, 25, and 26 to compounds A-35 to A-
45 is
shown in Fig. 6.
[0088] Compounds A-35 to A-38. These compounds were prepared from compound 24
(80
mg) in a mixture of the corresponding amine HaNR2 (0.4 mL) and NMP (1 mL),
75°C, 48 hr,
according to Procedure D.
[0089] Compounds A-39 and A-40. These compounds were prepared from compound ZS
(100 mg for compound A-39; 80 mg for compound A-40) in a mixture of the
corresponding
amine H2NR2 (0.5 mL for compound A-39; 0.4 mL for compound A-40) and NMP (0.5
mL
for compound A-39; 1 mL for compound A-40), 75°C, 48 hr, according to
Procedure D.
[0090] Compounds A-41 to A-45. These compounds were prepared from compound 26
(80
mg; except 100 mg for compound A-41) in a mixture of the corresponding amine
HaNRz (0.4
mL; except 0.5 mL for compound A-41) and NMP (1 mL; except 0.5 mL for A-41),
75°C, 48
hr, according to Procedure D.
Example D
[0091] This example describes the synthesis of compounds having a ring
nitrogen in the
benzofuryl unit, as exemplified by compound A-55.
[0092] The key step is a Sonogashira-type coupling of arylalkyne 29 to
iodopicolinol 27
(Fig. 7). The product of the C-C bond formation spontaneously undergoes a Pd-
mediated
cyclization to desired product 30. Deprotection of product 30 under acidic
conditions gave
aniline 31, which was coupled to acid chloride 6 to yield intermediate 32.
Nucleophilic
aromatic substitution at the isothiazole ring in intermediate 32 gave compound
A-55.
27
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0093] Compound 29. Compound 29 was prepared by Boc-protection of compound 28,
analogously to the preparation of compound 3.
[0094] Compound 30. A degassed (N2) suspension of picolinol 27 (0.50 g, 2. I2
mmol),
PdCl2(PPh3)2 (30 mg, 0.04 mmol), CuI (32 mg, 0.17 mmol), and PPh3 (44 mg, 0.16
mmol) in
Et3N (10 mL) was treated at RT with alkyne 28 (508 mg, 2.34 mmol) and stirred
at 70°C for 2
hr. Evaporation of the solvent and purification of the residual material by
flash
chromatography (hexane/AcOEt, 19:1 to 3:2 gradient) gave compound 30 (153 mg,
22%, 1H-
[0095] Compound 31. Compound 30 (100 mg) in AcOEt (4 mL, saturated with
anhydrous
HCl gas) was stirred at RT for 6 hr and diluted with EtaO (50 mL). The
resulting precipitate
was collected by filtration and dried to give compound 31 as a yellow solid
(85 ing, 93%, 1H-
NMR).
[0096] Compound A-S5. A mixture of acid chloride 6 (17.2 mg, 80 ~.mol) and
amine 31
(20 mg, 67 ~,mol) in NMP (0.33 mL) and DIEA (0.03 mL) was stirred at
60°C for 12 hr to
give compound 32, which was converted in situ to compound A-55 by treatment
with 3-
(dimethylamino)propylamine (1 mL), stirring at 70°C for 24 hr, dilution
with 50% aqueous
AcOH to a total volume of 15 mL and purification by HPLC (~H-NMR, ESI-MS).
Example E
[0097] This example describes the synthesis of compounds containing a
benzvthienyl
moiety. As shown in Fig. 8, the benzothienyl-containing biaryl unit was formed
under
Suzuki-type conditions starting from boronic acid 33 and iodoaniline 3.
[0098] CorrapomZd 34. Coupling of boronic acid 33 (I.SO g, 8.42 mmol) and
protected
iodoaniline 3 (2.44 g, 7.66 mmol) according to Procedure A gave biaryl
compound 34 (1.56
g, 63%, tan solid, 1H-NMR).
[0099] Compound 35. Deprotection of biaryl compound 34 (1.56 g) according to
Procedure
B gave 35 (>95%,1H-IVMR; contained residual TFA but used without further
purification).
[0100] Compouhd 36. Coupling of acid halide 6 (498 mg, 2.30 ri7rilol) and
compound 35
(650 mg, 1.92 mmol) according to Procedure C gave triaryl compound 36 (1H-
NMR).
[0101] Compound 37. Coupling of acid halide 8 (405 mg, 2.30 mmol) and compound
35
(650 mg, 1.92 mmol) according to Procedure C gave triaryl compound 37 (1H-
NMR).
28
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0102] The preparation of compounds A-46 to A-50 from triaryl intermediates 36
and 37 is
illustrated in Fig. 9.
[0103] Compounds A-46 and A-47. These compounds were prepared from compound 36
(80 mg) in a mixture of the corresponding amine HZNRZ (0.4 mL) and NMP (1 mL),
75°C, 48
hr, according to Procedure D.
[0104] Compounds A-48 to A-S0. These compounds were prepared from compound 37
(80
mg) in a mixture of the corresponding amine H2NRa (0.4 mL) and NMP (1 mL),
75°C, 48 hr,
according to Procedure D.
Example F
[0105] This example describes the synthesis of compounds containing a
benzothiazole
moiety from the commercially available compound 38 (Fig. 10).
[0106] Compound 39. A mixture of acid 7 (1.812 g, 9.20 mmol) and HBTU (3.314
g, 8.74
mmol) in DMF ( 10 mL) and DIEA (3 mL) was stirred at RT for 1 hr. The mixture
was added
to a solution of compound 38 (2.0 g, 8.32 mmol) in DMF (16 mL) and DIEA (2
mL). The
reaction mixture was stirred at 60°C for 24 hr and poured into stirred
ice-water (ca. 700 mL).
The resulting precipitate was collected by filtration and dried to give
compound 39 as a tan
solid (2.33 g) (1H-NMR; minor impurities but used without further
purification).
[0107] Compounds A-SI to A-54. These compounds were prepared according to
Procedure
D using compound 39 (100 mg), the corresponding amine H2NR2 (0.4 mL), NMP (1
mL),
and DIEA (0.1 mL).
Example G
[0108] This example describes the synthesis of compounds in which the biaryl
unit
contains an indole moiety.
[0109] ~ Fig. 11 shows the synthesis of intermediates 43 and 44.
[0110] Compound 41. Coupling of protected boronic acid 40 (1.00 g, 3.83 rnmol)
and
protected iodoaniline 3 (1.11 g, 3.48 mmol) according to Procedure A gave
compound 41
(1.19 g, 83%, tan solid, 1H-NMR).
29
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0111] Compound 42. Deprotection of compound 41 (1.19 g) according to
Procedure B
gave compound 42 (923 mg; >95%; 1H-NMR; contained residual TFA but used
without
further purification).
[OlI2] Compound 43. Coupling of acid halide 6 (378 mg, 1.75 mmol) and compound
42
(450 mg, I.40 mmol) according to Procedure C gave intermediate 43 (1H-NMR).
[OII3] Compound 44. Coupling of acid halide 8 (321 mg, 1.82 mmol) and compound
42
(470 mg, 1.46 mmol) according to Procedure C gave compound 44 (rH-NMR; minor
impurities but used without further purification).
[0114] Fig. 12 shows the conversion of compounds 43 and 44 to compounds of
this
invention.
[0115] Compounds A-56 and A-61. These compounds were prepared from compound 43
(70 mg) in a mixture of the corresponding amine HZNRa (0.4 mL) and NMP (1 mL),
75°C, 48
hr, according to Procedure D.
[0116] Compounds A-62 and A-66. These compounds were prepared from compound 44
(80 mg) in a mixture of the corresponding amine H2NR2 (0.4 mL) and NMP (1 mL),
75°C, 48
hr, according to Procedure D.
Exam lp a H
[0117] This example describes the synthesis of compounds in which the biaryl
moiety is a
benzothienyl-pyridyl moiety.
(0118] Fig. 13 shows the synthesis of intermediates 48 and 49.
[0119] C~mpound 46. Coupling of boronic acid 45 (2.00 g, 11.2 mmol) and
chloropyridine
21 (2.34 g, 10.2 mmol) according to Procedure A gave biaryl compound 46 (1.94
g, 58%,
white solid,'H-NMR).
[0120] Compound 47. Deprotection of biaryl compound 46 (2.40 g) according to
Procedure B gave compound 47 (2.40 g, orange solid, 1H-NMR, contained residual
TFA but
used without further purification).
(012I] Compound 48. Coupling of acid chloride 6 (525 mg, 2.42 mmol) and
compound 47
(750 mg, 2.20 mmol) according to Procedure C gave intermediate 48 (used
without
characterization).
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0122] Compound 49. Coupling of acid chloride 8 (427 mg, 2.42 mmol) and
compound 47
(750 mg, 2.20 mmol) according to Procedure C gave intermediate 49 (used
without
characterization).
[0123] Fig. 14 shows the conversion of intermediates 48 and 49 to compounds of
this
invention.
[0124] Compounds A-67 to A-71. These compounds were prepared from intermediate
48
(100 mg) in a mixture of the corresponding amine H2NR2 (0.5 mL) and NMP (0.5
mL), 75°C,
48 hr, according to Procedure D.
[0125] Compounds A-72 to A-76. These compounds were prepared from intermediate
49
(100 mg) in a mixture of the corresponding amine HZNRZ (0.5 rnL) and NMP (0.5
mL), 75°C,
48 hr, according to Procedure D.
Biological Activity
[0126] In vitro biological activity data were collected for a variety of
microorganisms,
including Bacillus tarsus (ATCC 11778), Staphylococcus aureus (ATCC 33591;
ATCC
27660, a methicillin resistant strain (MRSA); ATCC 13709, a methicillin
sensitive strain
(MSSA)), EschericlZia coli (ATCC 25922), EnteYOCOCCUS faecalis (ATCC 29212),
Streptococcus pneumoniae (ATCC 49619; ATCC 51422, a penicillin resistant
strain (PRSP)),
Enterococcus faecium (ATCC 51559, a vancomycin resistant strain (VRE)), and
Staphylococcus epidev~midis (ATCC I2228). Additionally, antifungal activity
data were
collected for Cart.dida albicans (ATCC 3 8247). Compounds of this invention
preferably have
an MIC of 4 or less against a drug resistant bacterial strain, such as one of
the foregoing (MRSA,
VRE, PRSP)
[0127] Compounds according to this invention were screened for their in vitro
activities
against selected species of bacteria and fungi. The minimal inhibition
concentration (MIC) of
these compounds was determined using the National Committee for Clinical
Laboratory
Standards (NCCLS) broth microdilution assay in microtiter plates, as set forth
in: (1) the
guidelines of the National Committee for Clinical Laboratory Standards (NCCLS)
Document
M7-A4 (NCCLS, 1997); (2) the guidelines of the National Committee for Clinical
Laboratory
Standards (NCCLS) Document Ml 1-A4 (NCCLS, 1997); and (3) the guidelines and
reference
method of the National Committee for Clinical Laboratory Standards (NCCLS)
Document M27-
31
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
T (NCCLS, 1995). For antifungal assays, the method recommended in Murray,
PR.,1995
Manual of Clinical Microbiology (ASM Press, Washington, DC.), was employed.
[0128] Preferably, compounds of this invention have an MIC of 4 or less
against at least
one strain of drug resistant bacteria. The results are presented in Table B
below, which is
keyed as follows:
Key to organisms tested against:
A = B. cereus ATCC 11778 B = C. albicarls ATCC 38247
C = E, faecalis ATCC 29212 D = S. aureus ATCC 13709
E = S. auf~eus ATCC 27660 F = S. aureus ATCC 33591
G = S epidermidis ATCC 12228 H = S. pneumoniae ATCC 49619
I = E. coli ATCC 25922
Key to activity:
+++=MIC <_4 ++=4<MIC<12
+ = 12 <_ MIC <_ 32 ND = not determined
>32 = preliminary data indicates MIC greater than 32
32
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table
B
-
Biological
Activity
(7rganism
(Minimum
Inhibitory
Concentration
(MIC),
~,g/mL)
Ref. A B C D E F G H I
A-1 +++ + +++ +++ +++ ND ND + >32
A-2 +++ ++ +++ +++ +++ +++ +++ + >32
A-3 + +++ +++ +++ +++ +++ +++ + >32
A-4 + + +++ +++ +++ ND ND >32 >32
A-5 ++ ++ +++ +++ +++ ND ND >32 >32
A-6 >32 ++ +++ +++ +++ ND ND >32 >32
A-7 +++ ++ +++ +++ +++ +++ +++ + >32
A-8 +++ ++ +++ +++ +++ +++ +++ + +
A-9 +++ + +++ +++ +++ ND ND + +
A-10 + >32 + ND ND ND ND + >32
A-11 +++ +++ +++ +++ +++ +++ +++ + >32
A-12 + + ++ ND ND ND + ++ >32
A-13 +++ + +++ +++ +++ ND ND + >32
A-14 >32 >32 >32 >32 >32 ND ND >32 >32
A-15 ++ + +++ +++ +++ ND ND + >32
A-16 >32 + ++ +++ +++ ND ND + >32
A-17 + + + ++ + ND ND + >32
A-18 +++ ++ ++ +++ +++ +++ +++ +++ >32
A-19 +++ ++ +++ +++ +++ +++ +++ + >32
A-20 + ++ + ++ ++ ND ND + +
A-21 ++ +++ +++ +++ +++ ND ND + >32
A-22 ++ +++ ++ ++ ++ ND ND + >32
A-23 +++ + +++ +++ +++ +++ ND + >32
A-24 >32 >32 + + + + ND >32 >32
A-25 >32 >32 + + + + ND >32 >32
33
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table
B
(continued)
Organism
(Minimum
Inhibitory
Concentration
(MIC),
wg/mL)
Ref. A B C D E F G H I
A-26 + >32 ++ +++ ++ ++ ND + >32
A-27 ++ ++ +++ +++ +++ +++ ND + >32
A-28 + + ++' ++ ++ ++ ND + >32
A-29 +++ + +++ +++ +++ +++ ND + >32
A-30 ++ +. +++ +++ +++ +++ ND + >32
A-31 ++ ++ +++ +++ +++ +++ ND + ++
A-32 >32 ++ +++ +++ +++ +++ +++ ND +
A-33 >32 + ++ +++ +++ + ND + >32
A-34 +++ +++ +++ +++ +++ +++ +++ + >32
A-35 >32 +++ + + + >32 ND >32 >32
A-36 ++ ++ ++ +++ + ++ ND + >32
A-37 >32 + ++ +++ +++ ++ ND >32 >32
A-38 +++ + +++ +++ +++ +++ ND >32 >32
A-39 + >32 + + + + ND + >32
A-40 + + ++ ++ ++ + ND >32 +
A-41 ++ ++ +++ +++ +++ +++ ND + ++
A-42 ++ >32 ++ ++ ++ ND ++ + >32
A-43 ++ >32 ++ ++ ++ ++ ND + >32
A-44 ++ ++ ++ ++ ++ ++ ND + >32
A-45 ++ ++ ++ +++ +++ +++ ~ + >32
A-46 >32 >32 >32 + + >32 ND >32 >32
A-47 >32 +++ +++ +++ +++ +++ +++ >32 >32
A-48 + >32 >32 +++ +++ +++ ND >32 >32
A-49 +++ +++ +++ +++ +++ +++ +++ + >32
A-50 +++ +++ +++ +++ +++ +++ +++ + >32
34
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
Table
B
(continued)
Organism
(Minimum
Inhibitory
Concentration
(MIC),
wg/mL)
Ref. A B C D E F G H I
A-S +++ +++ +++ +++ +++ ND ND +++ >32
I
A-52 + >32 +++ +++ ND +++ ND >32 >32
A-53 +++ >32 +++ +++ +++ +++ +++ >32 >32
A-54 +++ ,+++ +++ +++ +++ +++ ND + >32
A-55 + ++ + ++ ++ + ND + >32
A-56 >32 + + ++ ++ ++ ND >32 >32
A-57 + +++ ++ ++ ++ + ND >32 >32
A-5~ + +++ ++ + ++ ++ ND + >32
A-59 + +++ +++ ++ ++ + ND + >32
A-60 >32 >32 >32 >32 >32 >32 ND >32 >32
A-61 >32 +++ >32 >32 >32 >32 ND >32 >32
A-62 >32 >32 >32 >32 >32 >32 ND >32 >32
A-63 + ++ ++ ++ ++ ++ ND + >32
A-64 + + + + + + ND >32 +
A-65 + + + + + + ND >32 >32
A-66 >32 >32 >32 >32 >32 >32 ND >32 >32
A-67 +++ +++ +++ +++ +++ +++ ND >32 >32
A-6~ +++ +++ +++ +++ +++ +++ +++ >32 >32
A-69 >32 >32 >32 >32 >32 >32 ND >32 >32
A-70 >32 +++ +++ +++ +++ +++ ND >32 >32
A-71 +++ ++ +++ +++ +++ +++ ND + +++
A-72 >32 >32 >32 >32 >32 >32 ND >32 >32
A-73 >32 >32 >32 >32 >32 >32 ND >32 >32
A-74 + + ++ ++ + ++ ND + >32
A-75 +++ >32 +++ +++ +++ +++ ND + >32
A-76 + + ++ +++ +++ ++ ND + +
CA 02494139 2005-02-02
WO 2004/012736 PCT/US2003/024294
[0129] Table C shows additional antibacterial data for selected compounds,
against two
drug resistant bacterial strains: E. faeciufn (ATCC 51559, VRE) and S.
pneuynoniae (ATCC
51422, PRSP). (MIC values are keyed in the same manner as Table B.)
Table C - Additional
Antibacterial
Data
Compound Organism (Minimum Inhibitory
Concentration (MIC),
~,g/mL)
Reference E. faecium (ATCC 51559) S. pneumoniae (ATCC
51422)
A-2 +++ +
A-3 +++ +
A-7 +++ +
A-11 +++ +
A-34 +++ +
A-53 +++ +
A-6S +++ >32
[0130] The foregoing detailed description of the invention includes passages
that are
chiefly or exclusively concerned with particular parts or aspects of the
invention. It is to be
understood that this is for clarity and convenience, that a particular feature
may be relevant in
more than just the passage in which it is disclosed, and that the disclosure
herein includes all
the appropriate combinations of information found in the different passages.
Similarly,
although the various figures and descriptions herein relate to specific
embodiments of the
invention, it is to be understood that where a specific feature is disclosed
in the context of a
particular figure or embodiment, such feature can also be used, to the extent
appropriate, in
the context of another figure or embodiment, in combination with another
feature, or in the
invention in general.
[0131] Further, while the present invention has been particularly described in
terms of
certain preferred embodiments, the invention is not limited to such preferred
embodiments.
Rather, the scope of the invention is defined by the appended claims.
36
